DE69530196D1 - METHOD FOR PREVENTING THE AGGREGATION OF PROTEINS / PEPTIDES IN REHYDRATION OR THAWING - Google Patents

METHOD FOR PREVENTING THE AGGREGATION OF PROTEINS / PEPTIDES IN REHYDRATION OR THAWING

Info

Publication number
DE69530196D1
DE69530196D1 DE69530196T DE69530196T DE69530196D1 DE 69530196 D1 DE69530196 D1 DE 69530196D1 DE 69530196 T DE69530196 T DE 69530196T DE 69530196 T DE69530196 T DE 69530196T DE 69530196 D1 DE69530196 D1 DE 69530196D1
Authority
DE
Germany
Prior art keywords
thawing
aggregation
rehydration
peptides
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69530196T
Other languages
German (de)
Other versions
DE69530196T2 (en
Inventor
Joseph Roser
Camilo Colaco
Jaap Kampinga
Christopher Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Drug Delivery Ltd
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22958303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69530196(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Publication of DE69530196D1 publication Critical patent/DE69530196D1/en
Application granted granted Critical
Publication of DE69530196T2 publication Critical patent/DE69530196T2/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Freezing, Cooling And Drying Of Foods (AREA)

Abstract

The present invention encompasses methods to prevent aggregation of a wide variety of substances during freezing/thawing and/or dehydrating/rehydrating. The substances thus obtained and compositions comprising the substances are also encompassed by the invention.
DE69530196T 1994-06-02 1995-06-02 METHOD FOR PREVENTING THE AGGREGATION OF PROTEINS / PEPTIDES IN REHYDRATION OR THAWING Revoked DE69530196T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25296794A 1994-06-02 1994-06-02
PCT/GB1995/001277 WO1995033488A1 (en) 1994-06-02 1995-06-02 Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby

Publications (2)

Publication Number Publication Date
DE69530196D1 true DE69530196D1 (en) 2003-05-08
DE69530196T2 DE69530196T2 (en) 2003-11-20

Family

ID=22958303

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69530196T Revoked DE69530196T2 (en) 1994-06-02 1995-06-02 METHOD FOR PREVENTING THE AGGREGATION OF PROTEINS / PEPTIDES IN REHYDRATION OR THAWING

Country Status (10)

Country Link
US (2) US6890512B2 (en)
EP (1) EP0762897B1 (en)
JP (2) JP4142095B2 (en)
CN (1) CN1188171C (en)
AT (1) ATE235919T1 (en)
DE (1) DE69530196T2 (en)
DK (1) DK0762897T3 (en)
ES (1) ES2194911T3 (en)
PT (1) PT762897E (en)
WO (1) WO1995033488A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5621094A (en) * 1990-05-14 1997-04-15 Quadrant Holdings Cambridge Limited Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1995033488A1 (en) 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
JPH10508744A (en) 1994-09-22 1998-09-02 クオドラント ホールディングス ケンブリッジ リミテッド Compositions for hydration and nutritional use during athletics and methods of making the same
US6964771B1 (en) * 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
IL124275A (en) 1997-05-02 2002-03-10 Bio Merieux Vitek Inc Method for generating nucleic acid sequences
US6558901B1 (en) 1997-05-02 2003-05-06 Biomerieux Vitek Nucleic acid assays
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
RU2244556C2 (en) 1999-02-22 2005-01-20 Юниверсити Оф Коннектикут New albumin-free compositions of factor viii
FR2791895B1 (en) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
EP1458360B1 (en) 2001-12-19 2011-05-11 Novartis AG Pulmonary delivery of aminoglycosides
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
WO2003079993A2 (en) * 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
WO2005007282A2 (en) * 2003-05-13 2005-01-27 Minerva Biotechnologies Corporation Storage and use of colloids
JP4836797B2 (en) 2003-10-23 2011-12-14 大塚製薬株式会社 Controlled release sterile injection aripiprazole formulations and methods
EP1730516A1 (en) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
RU2008117396A (en) 2005-10-04 2009-11-10 Альк-Абелло А/С (Dk) SOLID VACCINE COMPOSITION
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
DK2131857T3 (en) * 2007-03-22 2015-09-14 Univ Colorado Regents A method of producing an immunologically active adjuvansbundet dried vaccine composition
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
BRPI0813698A2 (en) * 2007-07-09 2014-12-30 Novartis Ag CONSERVATION OF SECONDARY PEPTIDE STRUCTURE
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
AR067747A1 (en) 2007-07-31 2009-10-21 Otsuka Pharma Co Ltd METHODS TO PRODUCE SUSPENSION OF ARIPIPRAZOL AND LIOFILIZED FORMULATION
US20090081785A1 (en) * 2007-09-24 2009-03-26 Hememics Biotechnologies, Inc. Desiccated Biologics And Methods Of Preparing The Same
US20090090022A1 (en) * 2007-10-09 2009-04-09 Hememics Biotechnologies, Inc. Desiccation Chamber and Methods for Drying Biological Materials
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
JP4563476B2 (en) 2008-07-09 2010-10-13 パナソニック株式会社 Encoder, decoder and encoding method
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
JP5779780B2 (en) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Factor VIII formulation
US9827205B2 (en) * 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
US20120241356A1 (en) * 2009-07-06 2012-09-27 Sanofi-Aventis Deutschland Gmbh Heat- and vibration-stable insulin preparations
US9943075B2 (en) 2010-02-17 2018-04-17 Hememics Biotechnologies, Inc. Preservation solutions for biologics and methods related thereto
JP5341059B2 (en) * 2010-11-09 2013-11-13 株式会社大塚製薬工場 Stem cell suspension
ES2870529T3 (en) 2010-12-09 2021-10-27 Abbott Point Of Care Inc Apparatus that uses an anti-adsorption agent to facilitate mixing and analysis of samples
KR102374576B1 (en) * 2011-05-17 2022-03-15 솔리제닉스, 인크. Thermostable vaccine compositions and methods of preparing same
CN104023743B (en) 2011-10-25 2017-05-03 普罗西纳治疗有限公司 Antibody formulations and methods
US20150044251A1 (en) * 2011-12-23 2015-02-12 Novartis Ag Stable compositions for immunising against staphylococcus aureus
JP5432322B2 (en) * 2012-05-08 2014-03-05 株式会社大塚製薬工場 Mammalian cell suspension for prevention of pulmonary embolism containing trehalose
KR20150034170A (en) * 2012-06-25 2015-04-02 이머전트 프로덕트 디벨롭먼트 게이더스버그 인코포레이티드 Temperature stable vaccine formulations
WO2015100344A1 (en) 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
WO2016069173A2 (en) * 2014-09-29 2016-05-06 Cook General Biotechnology Llc Uses of trehalose in cell suspensions
WO2017172679A1 (en) * 2016-03-28 2017-10-05 Cook General Biotechnology Llc Viable cell compositions, and methods related to same
CN107307422B (en) * 2017-07-07 2018-09-18 许辉良 Instant Herba Dendrobii extract and preparation method thereof
CN107373663B (en) * 2017-07-07 2020-12-25 江西清源汉本生物科技有限公司 Instant chrysanthemum extract and preparation method thereof
CN107373662B (en) * 2017-07-07 2020-12-22 江西清源汉本生物科技有限公司 Instant honeysuckle extract and preparation method thereof
CA3078625C (en) 2017-10-09 2023-01-17 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US20200325020A1 (en) * 2017-10-25 2020-10-15 Merck Sharp & Dohme Corp. Adjuvanted vaccines
WO2020185916A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557717A (en) 1968-05-17 1971-01-26 Gen Mills Inc Process for making candy floss
US3619294A (en) 1968-07-15 1971-11-09 Penick & Ford Ltd Method of combining crystalline sugar with impregnating agents and products produced thereby
US3632357A (en) 1969-07-29 1972-01-04 Standard Brands Inc Method of producing hard candy
US3655442A (en) 1969-08-27 1972-04-11 California & Hawaiian Sugar Method of making sugar and sugar products
US4127502A (en) 1977-06-10 1978-11-28 Eastman Kodak Company Stabilizers for reconstituted, lyophilized samples
DE2748132A1 (en) 1977-10-27 1979-05-03 Behringwerke Ag STABILIZER FOR POLYSACCHARIDE
US4158544A (en) 1978-07-17 1979-06-19 Beckman Instruments, Inc. Process for preparing a biological composition for use as a reference control in diagnostic analysis
US4588744A (en) 1978-09-19 1986-05-13 Mchugh John E Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide
US4327076A (en) 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4327077A (en) 1981-05-29 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4883762A (en) 1983-06-06 1989-11-28 Ciba Corning Diagnostics Corp. Stabilized isoenzyme control products
US4865871A (en) 1983-08-23 1989-09-12 Board Of Regents The University Of Texas System Method for cryopreparing biological tissue
DE3445010A1 (en) 1984-12-10 1986-06-19 Boehringer Mannheim Gmbh CONTROL OR OAK SERUM FOR LIPID DIAGNOSTICS
DE229810T1 (en) 1985-07-09 1987-11-05 Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire PROTECTION OF PROTEINS AND SIMILAR.
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
US4762857A (en) 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
GB8715238D0 (en) * 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
CA1331133C (en) 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5262296A (en) * 1988-03-30 1993-11-16 Toray Industries, Inc. Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
GB8917470D0 (en) 1989-07-31 1989-09-13 Quadrant Bioresources Ltd Composition and method
AU650678B2 (en) 1990-08-10 1994-06-30 Analytical Control Systems, Inc. Stabilization (using gelatin from a cold water fish) of enzymes in diagnostic controls
US5200399A (en) 1990-09-14 1993-04-06 Boyce Thompson Institute For Plant Research, Inc. Method of protecting biological materials from destructive reactions in the dry state
US5242792A (en) * 1991-02-25 1993-09-07 The United States Of America As Represented By The Secretary Of The Navy Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides
US5422384A (en) 1992-11-25 1995-06-06 Battelle Memorial Institute Glass/polymer composites and methods of making
EP0717988B1 (en) 1993-08-20 2001-10-17 Nippon Shinyaku Company, Limited Gastric remaining preparation, swollen molding, and production process
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
WO1995033488A1 (en) * 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
AU713599B2 (en) 1995-06-07 1999-12-09 Quadrant Drug Delivery Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby

Also Published As

Publication number Publication date
JP4142095B2 (en) 2008-08-27
CN1156967A (en) 1997-08-13
JPH10500990A (en) 1998-01-27
DK0762897T3 (en) 2003-07-21
WO1995033488A1 (en) 1995-12-14
US20010055583A1 (en) 2001-12-27
DE69530196T2 (en) 2003-11-20
ES2194911T3 (en) 2003-12-01
US20050163750A1 (en) 2005-07-28
PT762897E (en) 2003-07-31
EP0762897B1 (en) 2003-04-02
US6890512B2 (en) 2005-05-10
JP2008179636A (en) 2008-08-07
EP0762897A1 (en) 1997-03-19
CN1188171C (en) 2005-02-09
ATE235919T1 (en) 2003-04-15

Similar Documents

Publication Publication Date Title
DE69530196D1 (en) METHOD FOR PREVENTING THE AGGREGATION OF PROTEINS / PEPTIDES IN REHYDRATION OR THAWING
ATE159429T1 (en) METHOD FOR DELIVERING AGENTS TO TARGET CELLS
DK332684D0 (en) MODIFIED PROTEASE INHIBITORS AND THEIR PREPARATION AND USE
ATE132164T1 (en) METHOD FOR INCREASE AND INHIBITING THE EFFECT OF AN INSULIN-LIKE GROWTH FACTOR
DE69231469D1 (en) USE OF GENTISIC ACID OR GENTISYL ALCOHOL TO STABILIZE RADIO-LABELED PEPTIDES AND PROTEINS
WO1998020133A3 (en) Proteins with enhanced levels of essential amino acids
DE69535948D1 (en) WDP-40 ABREGING PEPTIDES AND THEIR USE
NO891940D0 (en) PROCEDURE FOR SELECTIVE AA REDUCE PERMEABILITY OF OIL-FREE ZONES IN UNDERGRADUATE FORMS.
DK0572688T3 (en) Peptides, with organ-protective activity, method for their preparation and their use in therapy
MX9203519A (en) RECOMBINATION METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS AND DNA SEQUENCES USEFUL FOR THEM.
DE68927379D1 (en) SLIDE BLOCKING PEPTIDES
DK568287A (en) RELATIVELY LOW MOLECULAR PEPTIDES AND THEIR USE AS RENIN INHIBITORS
HUP9900506A2 (en) Prothrombin derivatives
ATE270305T1 (en) PEPTIDES OF THE ANTISECRETORIC FACTOR, WHICH REGULATES ILLEGAL CHANGES IN PERMEABILITY
DK0901526T3 (en) Cortistatin: neuropeptides, compositions and methods
DE68917837D1 (en) Peptide compounds.
ATE226591T1 (en) OLIGOPEPTIDES DERIVED FROM FRAGMENTS OF C-REACTIVE PROTEIN
NO892266L (en) AMBLYOMMIN, A NEW EFFECT FOR ANTICOAGULATION THERAPY.
FI891020A (en) Method for preparing eglin mutants with protease inhibitor activity
NO941377D0 (en) Cell cycle controlling preparations and methods for using them
HUT37557A (en) Presrving of spice paprika grist
ATE33718T1 (en) APPARATUS FOR THE SEQUENTIAL DEGRADATION OF PEPTIDES AND PROTEINS.
WO1998029436A3 (en) Lebetin peptides as platelet aggregation inhibitors

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: QUADRANT DRUG DELIVERY LTD., RUDDINGTON, NOTTINGHA

8331 Complete revocation